Eli Lilly and Co (LLY)
733.11
+8.24
(+1.14%)
USD |
NYSE |
Apr 26, 10:08
Eli Lilly SG&A Expense (Quarterly): 1.463B for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.463B |
September 30, 2023 | 1.804B |
June 30, 2023 | 1.810B |
March 31, 2023 | 1.633B |
December 31, 2022 | 1.270B |
September 30, 2022 | 1.614B |
June 30, 2022 | 1.531B |
March 31, 2022 | 1.465B |
December 31, 2021 | 1.519B |
September 30, 2021 | 1.505B |
June 30, 2021 | 1.615B |
March 31, 2021 | 1.503B |
December 31, 2020 | 1.497B |
September 30, 2020 | 1.455B |
June 30, 2020 | 1.413B |
March 31, 2020 | 1.505B |
December 31, 2019 | 1.646B |
September 30, 2019 | 1.360B |
June 30, 2019 | 1.536B |
March 31, 2019 | 1.461B |
December 31, 2018 | 1.626B |
September 30, 2018 | 1.395B |
June 30, 2018 | 1.431B |
March 31, 2018 | 1.283B |
December 31, 2017 | 1.495B |
Date | Value |
---|---|
September 30, 2017 | 1.515B |
June 30, 2017 | 1.666B |
March 31, 2017 | 1.504B |
December 31, 2016 | 1.668B |
September 30, 2016 | 1.565B |
June 30, 2016 | 1.623B |
March 31, 2016 | 1.474B |
December 31, 2015 | 1.798B |
September 30, 2015 | 1.576B |
June 30, 2015 | 1.635B |
March 31, 2015 | 1.524B |
December 31, 2014 | 1.800B |
September 30, 2014 | 1.672B |
June 30, 2014 | 1.664B |
March 31, 2014 | 1.485B |
December 31, 2013 | 1.954B |
September 30, 2013 | 1.652B |
June 30, 2013 | 1.868B |
March 31, 2013 | 1.652B |
December 31, 2012 | 1.978B |
September 30, 2012 | 1.757B |
June 30, 2012 | 1.931B |
March 31, 2012 | 1.848B |
December 31, 2011 | 2.133B |
September 30, 2011 | 1.918B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.270B
Minimum
Dec 2022
1.810B
Maximum
Jun 2023
1.534B
Average
1.505B
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 2.274B |
Biogen Inc | 581.50M |
Madrigal Pharmaceuticals Inc | 46.54M |
Vertex Pharmaceuticals Inc | 369.10M |
Viking Therapeutics Inc | 9.97M |